FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 2	20549	
-------------	--------	-------	--

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burd	len								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Halstead Michael</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ ITCI ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify						
(Last) C/O INT	•	irst) ULAR THERAF	(Middle) PIES, INC.		3. Date of Earliest Transaction (Month/Day/Year) 01/04/2016							below)	Officer (give title below)  EVP and Gen	below)	specify		
430 EAST 29TH STREET						4. If Amendment, Date of Original Filed (Month/Day/Year) 01/06/2016						Line	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) NEW YO	ORK N	Y	10016											iled by More	Reporting Perso		
(City)	(S	tate)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication											
									dicate that a trar e defense condi					on or written pl	lan that is intende	ed to	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			Execu Day/Year) if any		A. Deemed xecution Date, any /lonth/Day/Year		Code (Instr. 5)				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	/ Amoun	(A) o	Price	Transaci (Instr. 3	tion(s)		(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		on Date (e (Month/Day/Year) Exc if a (Mo	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$53.63	01/04/2016			A		40,472		01/04/2017 <sup>(1)</sup>	01/04/2026	Common Stock	40,472	\$0.00	40,472	D		

## **Explanation of Responses:**

1. The Stock Option vests as to one third of the shares on January 4, 2017, one third of the shares on January 4, 2018 and one third of the shares on January 4, 2019.

## Remarks:

This Form 4/A is being filed solely to correct an error in the number of shares underlying the stock option granted on January 4, 2016.

/s/ Lawrence J. Hineline, 07/07/2023 Attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.